Li Biao, Wang Xiaowei, Yang Chenguang, Wen Siqi, Li Jiajia, Li Na, Long Ying, Mu Yun, Liu Jianping, Liu Qin, Li Xuejun, Desiderio Dominic M, Zhan Xianquan
Key Laboratory of Cancer Proteomics of Chinese Ministry of Health, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008 People's Republic of China.
Science and Technology Innovation Center, Shandong First Medical University, 6699 Qingdao Road, Jinan, Shandong 250117 People's Republic of China.
EPMA J. 2021 Mar 3;12(1):67-89. doi: 10.1007/s13167-021-00232-7. eCollection 2021 Mar.
Human growth hormone (hGH) is synthesized, stored, and secreted by somatotroph cells in the pituitary gland, and promotes human growth and metabolism. Compared to a normal pituitary, a GH-secreting pituitary adenoma can secrete excessive GH to cause pathological changes in body tissues. GH proteoform changes would be associated with GH-related disease pathogenesis.
This study aimed to elucidate changes in GH proteoforms between GH-secreting pituitary adenomas and control pituitaries for the predictive diagnostics, targeted prevention, and personalization of medical services.
The isoelectric point (pI) and relative molecular mass (Mr) are two basic features of a proteoform that can be used to effectively array and detect proteoforms with two-dimensional gel electrophoresis (2DGE) and 2DGE-based western blot. GH proteoforms were characterized with liquid chromatography (LC) and mass spectrometry (MS). Phosphoproteomics, ubiquitinomics, acetylomics, and bioinformatics were used to analyze post-translational modifications (PTMs) of GH proteoforms in GH-secreting pituitary adenoma tissues and control pituitaries.
Sixty-six 2D gel spots were found to contain hGH, including 46 spots (46 GH proteoforms) in GH-secreting pituitary adenomas and 35 spots (35 GH proteoforms) in control pituitaries. Further, 35 GH proteoforms in control pituitary tissues were matched with 35 of 46 GH proteoforms in GH-secreting pituitary adenoma tissues; and 11 GH proteoforms were presented in only GH-secreting pituitary adenoma tissues but not in control pituitary tissues. The matched 35 GH proteoforms showed quantitative changes in GH-secreting pituitary adenomas compared to the controls. The quantitative levels of those 46 GH proteoforms in GH-secreting pituitary adenomas were significantly different from those 35 GH proteoforms in control pituitaries. Meanwhile, different types of PTMs were identified among those GH proteoforms. Phosphoproteomics identified phosphorylation at residues Ser77, Ser132, Ser134, Thr174, and Ser176 in hGH. Ubiquitinomics identified ubiquitination at residue Lys96 in hGH. Acetylomics identified acetylation at reside Lys171 in hGH. Deamination was identified at residue Asn178 in hGH.
These findings provide the first hGH proteoform pattern changes in GH-secreting pituitary adenoma tissues compared to control pituitary tissues, and the status of partial PTMs in hGH proteoforms. Those data provide in-depth insights into biological roles of hGH in GH-related diseases, and identify hGH proteoform pattern biomarkers for treatment of a GH-secreting pituitary adenoma in the context of 3P medicine -predictive diagnostics, targeted prevention, and personalization of medical services.
The online version contains supplementary material available at 10.1007/s13167-021-00232-7.
人生长激素(hGH)由垂体前叶的生长激素细胞合成、储存和分泌,可促进人体生长和新陈代谢。与正常垂体相比,分泌生长激素的垂体腺瘤可分泌过量的生长激素,导致身体组织发生病理变化。生长激素蛋白质变体的变化可能与生长激素相关疾病的发病机制有关。
本研究旨在阐明分泌生长激素的垂体腺瘤与对照垂体之间生长激素蛋白质变体的变化,以用于预测诊断、靶向预防和医疗服务个性化。
等电点(pI)和相对分子质量(Mr)是蛋白质变体的两个基本特征,可用于通过二维凝胶电泳(2DGE)和基于2DGE的蛋白质免疫印迹有效地排列和检测蛋白质变体。利用液相色谱(LC)和质谱(MS)对生长激素蛋白质变体进行表征。采用磷酸化蛋白质组学、泛素化蛋白质组学、乙酰化蛋白质组学和生物信息学方法分析分泌生长激素的垂体腺瘤组织和对照垂体中生长激素蛋白质变体的翻译后修饰(PTM)。
发现66个二维凝胶斑点含有hGH,其中分泌生长激素的垂体腺瘤中有46个斑点(46种生长激素蛋白质变体),对照垂体中有35个斑点(35种生长激素蛋白质变体)。此外,对照垂体组织中的35种生长激素蛋白质变体与分泌生长激素的垂体腺瘤组织中的46种生长激素蛋白质变体中的35种相匹配;11种生长激素蛋白质变体仅出现在分泌生长激素的垂体腺瘤组织中,而未出现在对照垂体组织中。与对照相比,匹配的35种生长激素蛋白质变体在分泌生长激素的垂体腺瘤中表现出定量变化。分泌生长激素的垂体腺瘤中46种生长激素蛋白质变体的定量水平与对照垂体中35种生长激素蛋白质变体的定量水平显著不同。同时,在这些生长激素蛋白质变体中鉴定出了不同类型的PTM。磷酸化蛋白质组学鉴定出hGH中Ser77、Ser132、Ser134、Thr174和Ser176残基处的磷酸化。泛素化蛋白质组学鉴定出hGH中Lys96残基处的泛素化。乙酰化蛋白质组学鉴定出hGH中Lys171残基处的乙酰化。在hGH的Asn178残基处鉴定出脱氨基。
这些发现首次揭示了分泌生长激素的垂体腺瘤组织与对照垂体组织相比生长激素蛋白质变体模式的变化,以及hGH蛋白质变体中部分PTM的状态。这些数据为hGH在生长激素相关疾病中的生物学作用提供了深入见解,并在预测诊断、靶向预防和医疗服务个性化的3P医学背景下,鉴定出用于治疗分泌生长激素的垂体腺瘤的hGH蛋白质变体模式生物标志物。
在线版本包含可在10.1007/s13167-021-00232-7获取的补充材料。